The telemedicine prescribing flexibilities from the COVID-19 public health emergency have been extended multiple times. Here is the current status as of November 2026, what the exceptions are, and what healthcare businesses need to do.
DEA Telemedicine Rules: What Healthcare Owners Need to Verify Now
This article reflects publicly available DEA and federal agency information as of November 15, 2026. Telemedicine prescribing rules for controlled substances have changed multiple times since 2020. Verify current requirements directly with the DEA at dea.gov and with qualified healthcare counsel before making prescribing decisions.
If your telehealth business prescribes controlled substances — testosterone, buprenorphine, stimulants, benzodiazepines, or other Schedule II through V medications — you need to understand the current DEA telemedicine rules. Not a summary from 2022. Not what your platform told you when you signed up. The current rules, verified against primary sources.
This is an area where the rules have changed repeatedly, where proposals have been confused with final rules, and where the consequences of getting it wrong are serious.
The Baseline: The Ryan Haight Act
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 is the federal statute that governs telemedicine prescribing of controlled substances. Its core requirement is straightforward: before a practitioner can prescribe a controlled substance via telemedicine, the practitioner must conduct at least one in-person medical evaluation of the patient.
This requirement applies to all Schedule II through V controlled substances. It applies regardless of the state where the patient is located or the state where the practitioner is licensed.
The Ryan Haight Act includes narrow statutory exceptions:
- The patient is being treated by and physically located in a DEA-registered hospital or clinic
- The patient is being treated in the physical presence of a DEA-registered practitioner
- The patient is being treated during a public health emergency declared by the Secretary of HHS
- The patient is being treated by a practitioner who has obtained a Special Registration from the DEA (this exception exists in the statute but the DEA has not yet issued final rules implementing it)
- Other narrow exceptions for Indian Health Service, Department of Veterans Affairs, and similar settings
The COVID-19 Public Health Emergency Flexibilities
During the COVID-19 public health emergency, the DEA exercised its authority under the Ryan Haight Act's public health emergency exception to allow telemedicine prescribing of controlled substances without a prior in-person evaluation. These flexibilities applied broadly and allowed telehealth businesses to prescribe controlled substances to new patients via telemedicine.
The COVID-19 public health emergency ended on May 11, 2023. The DEA has extended the telemedicine prescribing flexibilities multiple times through rulemaking to allow time for the Special Registration framework to be finalized. As of November 2026, verify the current extension status and expiration date directly with the DEA at dea.gov and in the Federal Register.
Do not assume the flexibilities are still in effect without verifying. Do not assume they have expired without verifying. The extension dates have changed multiple times, and any summary — including this one — may not reflect the most current status.
The Special Registration Framework
The Ryan Haight Act authorizes the DEA to create a Special Registration that would allow practitioners to prescribe controlled substances via telemedicine without a prior in-person evaluation. The DEA has been developing this framework since 2018.
As of November 2026, the DEA has not issued final rules implementing the Special Registration. The DEA has published proposed rules and has received public comments. The timeline for final rules is uncertain.
Until final rules are issued, the Special Registration exception in the Ryan Haight Act is not available. Practitioners cannot rely on it.
Testosterone: What Applies
Testosterone is a Schedule III controlled substance under the Controlled Substances Act. Prescribing testosterone via telemedicine is subject to the Ryan Haight Act requirements.
During the COVID-19 public health emergency flexibilities, telehealth businesses could prescribe testosterone to new patients without a prior in-person evaluation. Whether that flexibility is currently in effect depends on the current extension status.
If the flexibilities have expired or are not in effect, prescribing testosterone to a new patient via telemedicine without a prior in-person evaluation would generally not comply with the Ryan Haight Act, absent another applicable exception.
Verify current DEA guidance on testosterone prescribing via telemedicine before building or continuing a TRT telehealth service.
Buprenorphine: A Separate Analysis
Buprenorphine for opioid use disorder treatment has a separate regulatory history. The Consolidated Appropriations Act of 2023 eliminated the DATA 2000 waiver requirement (the "X-waiver") for buprenorphine prescribing. Any DEA-registered practitioner with Schedule III authority can now prescribe buprenorphine for opioid use disorder.
The telemedicine prescribing rules for buprenorphine have also been subject to specific DEA rulemaking. The DEA issued a final rule in 2024 that established specific conditions under which buprenorphine for opioid use disorder can be prescribed via telemedicine without a prior in-person evaluation. Verify the current requirements of that rule at dea.gov and in the Federal Register.
Buprenorphine prescribing rules are not identical to the general telemedicine controlled substance rules. Treat them as a separate analysis.
Psychiatric Medications: Stimulants and Benzodiazepines
Stimulants (amphetamines, methylphenidate) are Schedule II controlled substances. Benzodiazepines are Schedule IV. Both are subject to the Ryan Haight Act.
Telehealth businesses that prescribe stimulants for ADHD or benzodiazepines for anxiety via telemedicine need to verify whether the current DEA telemedicine flexibilities apply to their prescribing and what the current extension status is.
Schedule II controlled substances (stimulants) have additional restrictions beyond Schedule III through V. Verify the specific requirements for Schedule II prescribing via telemedicine.
Operational Implications
If you are operating a telehealth business that prescribes controlled substances, here are the questions to answer now:
Are the COVID-19 telemedicine flexibilities currently in effect? Verify at dea.gov and in the Federal Register. Do not rely on a summary or a platform's representation.
If the flexibilities expire, what is your plan? Do you have a process for conducting in-person evaluations for new patients? Do you have a referral network for patients who need in-person evaluation before a controlled substance can be prescribed?
Do your prescribers have active DEA registrations? Each prescriber must have their own DEA registration in the state where they are prescribing. Verify that registrations are current.
Are your prescribers registered in the right schedules? DEA registration specifies which schedules a practitioner is authorized to prescribe. Verify that each prescriber's registration covers the controlled substances they are prescribing.
What are the state-specific requirements? State law may impose additional requirements on telemedicine prescribing of controlled substances beyond the federal Ryan Haight Act requirements. Verify the requirements in every state where your prescribers practice.
Where to Verify
- DEA telemedicine information: dea.gov/diversion-control-division/telemedicine
- DEA press releases on telemedicine extensions: dea.gov/press-releases
- Federal Register for current rules and proposed rules: federalregister.gov (search "DEA telemedicine")
- HHS SAMHSA for buprenorphine-specific guidance: samhsa.gov
If you want to review your telehealth prescribing structure and understand what the current rules mean for your business, I can help with that analysis.
Frequently Asked Questions
What is the Ryan Haight Act? The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in-person medical evaluation before a practitioner can prescribe a controlled substance via telemedicine. It includes narrow statutory exceptions. It is codified at 21 U.S.C. § 829(e).
Are the COVID-19 telemedicine prescribing flexibilities still in effect? As of the date of this article, verify the current status directly at dea.gov. The flexibilities have been extended multiple times, and the current extension status and expiration date may have changed since this article was written.
What is the DEA Special Registration? The Ryan Haight Act authorizes the DEA to create a Special Registration that would allow telemedicine prescribing of controlled substances without a prior in-person evaluation. As of November 2026, the DEA has not issued final rules implementing the Special Registration. It is not currently available.
Do the telemedicine rules apply to all controlled substances equally? No. Different schedules have different restrictions. Buprenorphine for opioid use disorder has been subject to specific rulemaking. Schedule II controlled substances have additional restrictions. Verify the specific requirements for each controlled substance category.
What happens if I prescribe a controlled substance via telemedicine in violation of the Ryan Haight Act? Violations of the Ryan Haight Act can result in DEA enforcement action, including revocation of DEA registration, civil penalties, and criminal prosecution. The consequences are serious. Verify compliance before prescribing.
Explore Topics
Written by
AJ Pakpour
AJ Pakpour is a healthcare entrepreneur, Vice President of Doctor Staffers, founder of AmeraCell, and creator of The Business of Modern Medicine, with 25+ years of experience building and advising healthcare businesses.